Literature DB >> 10606054

Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis.

K Poikolainen1, J Karvonen, E Pukkala.   

Abstract

BACKGROUND: Psoriasis is seen as a disease that does not kill. However, it is associated with alcohol intake and smoking. Thus, there could be excess mortality due to causes related to alcohol intake and smoking among patients with psoriasis.
DESIGN: A cohort was identified from the nationwide Hospital Discharge Register from January 1, 1973, through December 31, 1984, and mortality was followed up for 22 years by linkage with the Cause-of-Death Register, from January 1, 1973, through December 31, 1995. PATIENTS: A cohort of 3132 men and 2555 women admitted to inpatient treatment with psoriasis as the principal diagnosis. MAIN OUTCOME MEASURES: Date and underlying cause of death.
RESULTS: We observed 1918 deaths in contrast to the 1211 deaths expected on the basis of the national mortality rates. The all-cause standardized mortality ratio (SMR) for men was 1.62 (95% confidence interval [CI], 1.52-1.71); for women, 1.54 (95% CI, 1.43-1.64). Among men, the highest SMRs were found for alcohol psychosis (8.91 [95% CI, 2.89-20.70]) and liver disease, ie, cirrhosis, fatty liver, and hepatitis (6.98 [95% CI, 5.34-8.96]). Among women, the highest SMR was found for liver disease (5.06 [95% CI, 2.70-8.65]). Excess mortality was high for all causes of death directly related to alcohol; the SMR for men was 4.46 (95% CI, 3.60-5.45); for women, 5.60 (95% CI, 2.98-8.65).
CONCLUSIONS: Patients with moderate to severe psoriasis are at increased risk for death. Alcohol is a major cause for this excess mortality.

Entities:  

Mesh:

Year:  1999        PMID: 10606054     DOI: 10.1001/archderm.135.12.1490

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  44 in total

1.  Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients.

Authors:  R M Fernandez-Torres; S Paradela; E Fonseca
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

Review 2.  Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Authors:  Lotus Mallbris; Christopher T Ritchlin; Mona Ståhle
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 3.  Psoriasis and its management.

Authors:  Catherine H Smith; J N W N Barker
Journal:  BMJ       Date:  2006-08-19

Review 4.  Environmental Basis of Autoimmunity.

Authors:  Annarosa Floreani; Patrick S C Leung; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

5.  Pediatric Psoriasis Comorbidity Screening Guidelines.

Authors:  Emily Osier; Audrey S Wang; Megha M Tollefson; Kelly M Cordoro; Stephen R Daniels; Andrew Eichenfield; Joel M Gelfand; Alice B Gottlieb; Alexa B Kimball; Mark Lebwohl; Nehal N Mehta; Amy S Paller; Jeffrey B Schwimmer; Dennis M Styne; Abby S Van Voorhees; Wynnis L Tom; Lawrence F Eichenfield
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

6.  Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study.

Authors:  Megan H Noe; Daniel B Shin; Marilyn T Wan; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2017-08-23       Impact factor: 8.551

7.  Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis.

Authors:  Wenqing Li; Jiali Han; Hyon K Choi; Abrar A Qureshi
Journal:  Am J Epidemiol       Date:  2012-01-12       Impact factor: 4.897

8.  Trends in incidence of adult-onset psoriasis over three decades: a population-based study.

Authors:  Murat Icen; Cynthia S Crowson; Marian T McEvoy; Frank J Dann; Sherine E Gabriel; Hilal Maradit Kremers
Journal:  J Am Acad Dermatol       Date:  2009-03       Impact factor: 11.527

9.  Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo.

Authors:  Malgorzata Romanowska; Louise Reilly; Colin N A Palmer; Mattias C U Gustafsson; John Foerster
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

10.  Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.

Authors:  G R Burmester; P Mease; B A C Dijkmans; K Gordon; D Lovell; R Panaccione; J Perez; A L Pangan
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.